Erythropoietin mimics ischemic preconditioning

Vascular Pharmacology

Volumn 42, Issue 5-6, 2005, Pages 233-241

  Baker, John E ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Cardioprotection; Dosing considerations; Erythopoietin; Heart; Myocardial infarction; Myocardial ischemia; Nitric oxide; Nitric oxide synthase; Potassium channels; Protein kinases; Timing considerations

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 HYDROXYDECANOIC ACID; CHELERYTHRINE; GLIBENCLAMIDE; PAXILLINE; POTASSIUM CHANNEL; RECOMBINANT ERYTHROPOIETIN; WORTMANNIN;

DRUG DOSE REGIMEN; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW;

ANIMALS; ERYTHROPOIETIN; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; SIGNAL TRANSDUCTION;

EID: 19444372033     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2005.02.004     Document Type: Review

References (75)

1. J. Alblas, R. Slager-Davidov, P.H. Steenbergh, J.S. Sussenbach, and B. van der Burg The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells Oncogene 16 1 1998 131 139
2. F. Ammarguellat, M. Llovera, P.A. Kelly, and V. Goffin Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells Biochem. Biophys. Res. Commun. 284 4 2001 1031 1038
3. F.H. Bahlmann, K. De Groot, J.M. Spandau, A.L. Landry, B. Hertel, T. Duckert, S.M. Boehm, J. Menne, H. Haller, and D. Fliser Erythropoietin regulates endothelial progenitor cells Blood 103 3 2004 921 926
4. F.H. Bahlmann, R. Song, S.M. Boehm, M. Mengel, R. von Wasielewski, C. Lindschau, T. Kirsch, K. de Groot, R. Laudeley, E. Niemczyk, F. Guler, J. Menne, H. Haller, and D. Fliser Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure Circulation 110 8 2004 1006 1012
5. J.E. Baker, B.D. Curry, G.N. Olinger, and G.J. Gross Increased tolerance of the chronically hypoxic immature heart to ischemia. Contribution of the KATP channel Circulation 95 5 1997 1278 1285
6. A. Besarab, W.K. Bolton, J.K. Browne, J.C. Egrie, A.R. Nissenson, D.M. Okamoto, S.J. Schwab, and D.A. Goodkin The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N. Engl. J. Med. 339 9 1998 584 590
7. A.K. Boer, A.L. Drayer, H. Rui, and E. Vellenga Prostaglandin-E2 enhances EPO-mediated STAT5 transcriptional activity by serine phosphorylation of CREB Blood 100 2 2002 467 473
8. G.W. Booz, J.N. Day, and K.M. Baker Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure J. Mol. Cell Cardiol. 34 11 2002 1443 1453
9. G.W. Booz, J.N. Day, R. Speth, and K.M. Baker Cytokine G-protein signaling crosstalk in cardiomyocytes: attenuation of Jak-STAT activation by endothelin-1 Mol. Cell Biochem. 240 1-2 2002 39 46
10. A. Braun, R. Ding, C. Seidel, T. Fies, A. Kurtz, and K. Scharer Pharmacokinetics of recombinant human erythropoietin applied subcutaneously to children with chronic renal failure Pediatr. Nephrol. 7 1 1993 61 64
11. M. Brines, P. Ghezzi, S. Keenan, D. Agnello, N. de Lanerolle, C. Cerami, L. Itri, and A. Cerami Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury PNAS 97 19 2000 10526 10531
12. Z. Cai, and G.L. Semenza Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury Circulation 109 17 2004 2050 2053
13. Z. Cai, D.J. Manalo, G. Wei, E.R. Rodriguez, K. Fox-Talbot, H. Lu, J.L. Zweier, and G.L. Semenza Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury Circulation 108 1 2003 79 85
14. N. Cakar, M. Ekim, N. Tumer, F. Yalcinkaya, N. Akar, and H.O. Onaran Pharmacokinetics of recombinant human erythropoietin in children with chronic renal failure Int. Urol. Nephrol. 29 3 1997 377 383
15. L. Calvillo, R. Latini, J. Kajstura, A. Leri, P. Anversa, P. Ghezzi, M. Salio, A. Cerami, and M. Brines Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling Proc. Natl. Acad. Sci. U. S. A. 100 8 2003 4802 4806
16. M.P. Carroll, and W.S. May Protein kinase C-mediated serine phosphorylation directly activates Raf-1 in murine hematopoietic cells J. Biol. Chem. 269 2 1994 1249 1256
17. C. Chen, and A.J. Sytkowski Erythropoietin activates two distinct signaling pathways required for the initiation and the elongation of c-myc J. Biol. Chem. 276 42 2001 38518 38526
18. W.C. Cole, C.D. McPherson, and D. Sontag ATP-regulated K + channels protect the myocardium against ischemia/reperfusion damage Circ. Res. 69 3 1991 571 581
19. J.E. Damen, A.L. Mui, L. Puil, T. Pawson, and G. Krystal Phosphatidylinositol 3-kinase associates, via its Src homology 2 domains, with the activated erythropoietin receptor Blood 81 12 1993 3204 3210
20. J.E. Damen, R.L. Cutler, H. Jiao, T. Yi, and G. Krystal Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the P85 subunit of phosphatidylinositol (PI) 3-kinase and for EpR-associated PI 3-kinase activity J. Biol. Chem. 270 40 1995 23402 23408
21. E. Devemy, C. Billat, and B. Haye Activation of Raf-1 and mitogen-activated protein kinases by erythropoietin and inositolphosphate-glycan in normal erythroid progenitor cells: involvement of protein kinase C Cell. Signal. 9 1 1997 41 46
22. M. Digicaylioglu, and S.A. Lipton Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades Nature 412 6847 2001 641 647
23. H. Dolznig, B. Habermann, K. Stangl, E.M. Deiner, R. Moriggl, H. Beug, and E.W. Mullner Apoptosis protection by the Epo target Bcl-X(L) allows factor-independent differentiation of primary erythroblasts Curr. Biol. 12 13 2002 1076 1085
24. B.L. Ebert, and H.F. Bunn Regulation of the erythropoietin gene Blood 94 6 1999 1864 1877
25. J.W. Eschbach, J.C. Egrie, M.R. Downing, J.K. Browne, and J.W. Adamson Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial N. Engl. J. Med. 316 2 1987 73 78
26. J.H. Evans, J.T. Brocklebank, C.J. Bowmer, and P.C. Ng Pharmacokinetics of recombinant human erythropoietin in children with renal failure Nephrol. Dial. Transplant. 6 10 1991 709 714
27. C. Figueroa, and A.B. Vojtek Akt negatively regulates translation of the ternary complex factor Elk-1 Oncogene 22 36 2003 5554 5561
28. C. Figueroa, S. Tarras, J. Taylor, and A.B. Vojtek Akt2 negatively regulates assembly of the POSH-MLK-JNK signaling complex J. Biol. Chem. 278 48 2003 47922 47927
29. + channels. Potential mechanism of cardioprotection Circ. Res. 81 1997 1072 1082
30. P. Geva, and J. Sherwood Pharmacokinetics and pharmacodynamics of recombinant human erythropoeitin in children with chronic renal failure Int. Urol. Nephrol. 29 1991 377 383
31. S. Gobert, V. Duprez, C. Lacombe, S. Gisselbrecht, and P. Mayeux The signal transduction pathway of erythropoietin involves three forms of mitogen-activated protein (MAP) kinase in UT7 erythroleukemia cells Eur. J. Biochem. 234 1 1995 75 83
32. D.J. Hausenloy, M.M. Mocanu, and D.M. Yellon Ischemic preconditioning protects by activating pro-survival kinases at reperfusion Am. J. Phsyiol. Heart Circ. Physiol. 2004
33. E. Hu, J.B. Kim, P. Sarraf, and B.M. Spiegelman Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma Science 274 5295 1996 2100 2103
34. B.H. Jiang, M. Aoki, J.Z. Zheng, J. Li, and P.K. Vogt Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B Proc. Natl. Acad. Sci. U. S. A. 96 5 1999 2077 2081
35. A.T. Kausz, S.L. Watkins, C. Hansen, D.A. Godwin, R.B. Palmer, and J.R. Brandt Intraperitoneal erythropoietin in children on peritoneal dialysis: a study of pharmacokinetics and efficacy Am. J. Kidney Dis. 34 4 1999 651 656
36. A. Kis, D.M. Yellon, and G.F. Baxter Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase J. Mol. Cell. Cardiol. 35 9 2003 1063 1071
37. U. Klingmuller, H. Wu, J.G. Hsiao, A. Toker, B.C. Duckworth, L.C. Cantley, and H.F. Lodish Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors Proc. Natl. Acad. Sci. U. S. A. 94 7 1997 3016 3021
38. H. Kouchi, K. Nakamura, K. Fushimi, M. Sakaguchi, M. Miyazaki, T. Ohe, and M. Namba Manumycin A, inhibitor of ras farnesyltransferase, inhibits proliferation and migration of rat vascular smooth muscle cells Biochem. Biophys. Res. Commun. 264 3 1999 915 920
39. S.T. Koury, M.J. Koury, M.C. Bondurant, J. Caro, and S.E. Graber Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration Blood 74 2 1989 645 651
40. C. Lacombe, J.L. Da Silva, P. Bruneval, J.G. Fournier, F. Wendling, N. Casadevall, J.P. Camilleri, J. Bariety, B. Varet, and P. Tambourin Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney J. Clin. Invest. 81 2 1988 620 623
41. M. Leist, P. Ghezzi, G. Grasso, R. Bianchi, P. Villa, M. Fratelli, C. Savino, M. Bianchi, J. Nielsen, J. Gerwien, P. Kallunki, A.K. Larsen, L. Helboe, S. Christensen, L.O. Pedersen, M. Nielsen, L. Torup, T. Sager, A. Sfacteria, S. Erbayraktar, Z. Erbayraktar, N. Gokmen, O. Yilmaz, C. Cerami-Hand, Q.W. Xie, T. Coleman, A. Cerami, and M. Brines Derivatives of erythropoietin that are tissue protective but not erythropoietic Science 305 5681 2004 239 242
42. D.F. Liao, B. Monia, N. Dean, and B.C. Berk Protein kinase C-zeta mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells J. Biol. Chem. 272 10 1997 6146 6150
43. E. Lipsic, P. van der Meer, R.H. Henning, A.J. Suurmeijer, K.M. Boddeus, D.J. van Veldhuisen, W.H. van Gilst, and R.G. Schoemaker Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion J. Cardiovasc. Pharmacol. 44 4 2004 473 479
44. D.M. Mancini, S.D. Katz, C.C. Lang, J. LaManca, A. Hudaihed, and A.S. Androne Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure Circulation 107 2 2003 294 299
45. N.R. Michaud, J.R. Fabian, K.D. Mathes, and D.K. Morrison 14-3-3 is not essential for Raf-1 function: identification of Raf-1 proteins that are biologically activated in a 14-3-3- and Ras-independent manner Mol. Cell. Biol. 15 6 1995 3390 3397
46. Y. Miura, O. Miura, J.N. Ihle, and N. Aoki Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor J. Biol. Chem. 269 47 1994 29962 29969
47. G. Montini, G. Zacchello, and F. Perfumo Pharmacokinetics and pharmacodynamics of subcutaneous administration of rHuEPO on CPD. A multicenter study fromt he Italian Registry of Pediatric CPD J. Am. Soc. Nephrol. 2 1991 283
48. C. Moon, M. Krawczyk, D. Ahn, I. Ahmet, D. Paik, E.G. Lakatta, and M.I. Talan Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats Proc. Natl. Acad. Sci. U. S. A. 100 20 2003 11612 11617
49. A.J. Muslin, J.W. Tanner, P.M. Allen, and A.S. Shaw Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine Cell 84 6 1996 889 897
50. + channels in cardiac muscle Nature 305 5930 1983 147 148
51. Y. Okutani, A. Kitanaka, T. Tanaka, H. Kamano, H. Ohnishi, Y. Kubota, T. Ishida, and J. Takahara Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway Oncogene 20 45 2001 6643 6650
52. T. Omura, M. Yoshiyama, F. Ishikura, H. Kobayashi, K. Takeuchi, S. Beppu, and J. Yoshikawa Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats J. Mol. Cell. Cardiol. 33 2 2001 307 316
53. C.J. Parsa, A. Matsumoto, J. Kim, R.U. Riel, L.S. Pascal, G.B. Walton, R.B. Thompson, J.A. Petrofski, B.H. Annex, J.S. Stamler, and W.J. Koch A novel protective effect of erythropoietin in the infarcted heart J. Clin. Invest. 112 7 2003 999 1007
54. C.J. Parsa, J. Kim, R.U. Riel, L.S. Pascal, R.B. Thompson, J.A. Petrofski, A. Matsumoto, J.S. Stamler, and W.J. Koch Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts J. Biol. Chem. 279 20 2004 20655 20662
55. P. Rafiee, Y. Shi, X. Kong, K. Pritchard Jr., J. Tweddell, S. Litwin, K. Mussatto, R. Jaquiss, J. Su, and J. Baker Activation of protein kinases in chronically hypoxic infant human and rabbit hearts: role in cardioprotection Circulation 106 2002 239 245
56. Rafiee, P., Shi, Y., Su, J., Pritchard, Jr. K., Tweddell, J.S., Baker, J.E., in press. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res. Cardiol.
57. R.E. Reddingius, C.H. Schroder, A.M. Koster, and L.A. Monnens Pharmacokinetics of recombinant human erythropoietin in children treated with continuous ambulatory peritoneal dialysis Eur. J. Pediatr. 153 11 1994 850 854
58. P. Rodriguez-Viciana, P.H. Warne, A. Khwaja, B.M. Marte, D. Pappin, P. Das, M.D. Waterfield, A. Ridley, and J. Downward Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras Cell 89 3 1997 457 467
59. F.T. Ruschitzka, R.H. Wenger, T. Stallmach, T. Quaschning, C. de Wit, K. Wagner, R. Labugger, M. Kelm, G. Noll, T. Rulicke, S. Shaw, R.L. Lindberg, B. Rodenwaldt, H. Lutz, C. Bauer, T.F. Luscher, and M. Gassmann Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin Proc. Natl. Acad. Sci. U. S. A. 97 21 2000 11609 11613
60. Y. Shi, P. Rafiee, J. Su, K. Pritchard Jr., J. Tweddell, and J. Baker Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels Basic Res. Cardiol. 99 2004 173 182
61. D.S. Silverberg, D. Wexler, M. Blum, G. Keren, D. Sheps, E. Leibovitch, D. Brosh, S. Laniado, D. Schwartz, T. Yachnin, I. Shapira, D. Gavish, R. Baruch, B. Koifman, C. Kaplan, S. Steinbruch, and A. Iaina The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations J. Am. Coll. Cardiol. 35 7 2000 1737 1744
62. A. Stephanou, B.K. Brar, T.M. Scarabelli, A.K. Jonassen, D.M. Yellon, M.S. Marber, R.A. Knight, and D.S. Latchman Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis J. Biol. Chem. 275 14 2000 10002 10008
63. P.A. Tilbrook, S.M. Colley, D.J. McCarthy, R. Marais, and S.P. Klinken Erythropoietin-stimulated Raf-1 tyrosine phosphorylation is associated with the tyrosine kinase Lyn in J2E erythroleukemic cells Arch. Biochem. Biophys. 396 1 2001 128 132
64. K. Todokoro, M. Sugiyama, E. Nishida, and K. Nakaya Activation of mitogen-activated protein kinase cascade through erythropoietin receptor Biochem. Biophys. Res. Commun. 203 3 1994 1912 1919
65. A.F. Tramontano, R. Muniyappa, A.D. Black, M.C. Blendea, I. Cohen, L. Deng, J.R. Sowers, M.V. Cutaia, and N. El-Sherif Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway Biochem. Biophys. Res. Commun. 308 4 2003 990 994
66. B.R. Walker, T.C. Resta, and L.D. Nelin Nitric oxide-dependent pulmonary vasodilation in polycythemic rats Am. J. Phsyiol. Heart Circ. Physiol. 279 5 2000 H2382 H2389
67. G.L. Wright, P. Hanlon, K. Amin, C. Steenbergen, E. Murphy, and M.O. Arcasoy Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury FASEB J. 18 9 2004 1031 1033
68. N.C. Wrighton, F.X. Farrell, R. Chang, A.K. Kashyap, F.P. Barbone, L.S. Mulcahy, D.L. Johnson, R.W. Barrett, L.K. Jolliffe, and W.J. Dower Small peptides as potent mimetics of the protein hormone erythropoietin Science 273 5274 1996 458 464
69. N.C. Wrighton, P. Balasubramanian, F.P. Barbone, A.K. Kashyap, F.X. Farrell, L.K. Jolliffe, R.W. Barrett, and W.J. Dower Increased potency of an erythropoietin peptide mimetic through covalent dimerization Nat. Biotechnol. 15 12 1997 1261 1265
70. X.C. Wu, E.J. Johns, and N.T. Richards Relationship between erythropoietin and nitric oxide in the contraction of rat renal arcuate arteries and human umbilical vein endothelial cells Clin. Sci. (Lond.) 97 4 1999 413 419
71. + channels in the cardiac inner mitochondrial membrane Science 298 5595 2002 1029 1033
72. Y.T. Xuan, Y. Guo, H. Han, Y. Zhu, and R. Bolli An essential role of the JAK-STAT pathway in ischemic preconditioning Proc. Natl. Acad. Sci. U. S. A. 98 16 2001 9050 9055
73. G. Yamaura, T. Turoczi, F. Yamamoto, M.A. Siddqui, N. Maulik, and D.K. Das STAT signaling in ischemic heart: a role of STAT5A in ischemic preconditioning Am. J. Physiol. Heart Circ. Physiol. 285 2 2003 H476 H482
74. H. Youssoufian, G. Longmore, D. Neumann, A. Yoshimura, and H.F. Lodish Structure, function, and activation of the erythropoietin receptor Blood 81 9 1993 2223 2236
75. S. Zimmermann, and K. Moelling Phosphorylation and regulation of Raf by Akt (protein kinase B) Science 286 5445 1999 1741 1744